Does Chamomile Green Tea Work For Facial Redness?

facial redness

Mild redness is usually not serious; however, it can be the cause of loss of self-confidence. But do not worry. We have a home remedy for you that can help you deal with facial redness.

facial redness

The redness may be due to a skin condition, such as rosacea or endocrine disorders that aren’t easy to identify. (Source: Freepik)

Red, flushed skin can be caused by a number of factors, from hot weather to an intense workout to just plain embarrassment. But often the redness it may be due to a skin condition, such as rosacea or endocrine disorders that are not easy to identify.

Speaking about the skin condition, Dr Mamta Dhayal, MBBS, DDV, Dr Dhayals Skin Clinic, Mumbai said: ‘Facial redness can manifest itself as the presence of visible blood vessels, uneven texture of the skin around the nose or a red appearance cheeks These visual cues result from dilation of facial blood vessels, which can be attributed to various factors such as allergies, aging, sun damage, prolonged dry skin, or infections, adding that exposure to sunlight can contribute to redness flare-ups of the face because the ultraviolet radiation present in sunlight can aggravate the condition and intensify the redness.

While a slight flush is usually not serious, it can be the cause of loss of self-confidence. But do not worry. We have a home remedy for you that can help you deal with facial redness.

Sharing a tip for the same, Dr Manjot Marwah, a dermatologist, took to Instagram. A homemade trick to reduce redness on the face is chamomile green tea. Then, she has bisabolol, which is a great antioxidant that can help reduce rosacea and redness, she said.

However, she pointed out that there is a particular way you need to brew chamomile green tea. Beer green tea for facial toners it’s a simple process that requires just four simple steps.

*First, you’ll need to get some green tea, either loose leaf or in bags. We recommend loose leaves if possible as they have a higher concentration of antioxidants.

*Second, heat the water until it starts to boil. Not Boil the water for too long as this can reduce some of the beneficial properties of the tea.

* Third, steep the tea leaves in hot water for five minutes to get a strong extraction of the antioxidants and other beneficial compounds.

*Finally, strain the tea and let it cool before applying it to your face. When the tea is cool enough to touch, you can rub it on your face with a cotton ball or pad. Let the green tea sit on your face for five minutes before rinsing it off fresh water.

This blend can be used commercially when preserved with a preservative called BHT, which is available in most cosmeceuticals. Use it for at least 2-4 weeks before you start seeing results, noted Dr. Marwah.

Chamomile green tea contains antioxidants and anti-inflammatory compounds such as bisabolol and chamazulene. (Source: Freepik)

Explaining the benefits of chamomile green tea, Dr. Ramdas, Senior Dermatologist, Kamineni Hospitals, Hyderabad said, “It can help manage facial redness to some extent as it helps soothe the skin and reduce redness.” Chamomile green tea contains antioxidants and anti-inflammatory compounds such as bisabolol and chamazulene. These properties can help reduce inflammation and redness. However, he stressed that it’s important to note that individual results may vary and it’s always advisable to consult a dermatologist for an individualized treatment plan.

Additionally, Dr. Ramdas has recommended other methods to treat facial flushing, including:

*Using mild skin care products suitable for sensitive skin.
* Avoid triggers such as hot water, harsh soaps, and excessive sun exposure.
*Applying a cold compress or using over-the-counter creams or ointments recommended by a dermatologist.
*In some cases, prescription medication or laser treatments it could be necessary.

For more lifestyle news, follow us on Instagram | Chirping | Facebook and don’t miss the latest updates!

IE Online Media Services Pvt Ltd

First published on: 2023-06-07 at 18:20 CEST



#Chamomile #Green #Tea #Work #Facial #Redness

Can Ginger Oil Melt Belly Fat? No. Trendy solutions don’t always work

ginger oil

By reducing bloating and improving digestive function, ginger may contribute to a flatter tummy appearance, but it won’t specifically target fat in that area. For this you need a holistic plan of balanced diet, exercise and lifestyle modification, says Dr. Harsh Kapoor, president (Pan Metro)-Institute of Gastroenterology, Hepatology, GI Surgery & Liver Transplant, Metro Hospital, Noida

ginger oil

Ginger alone cannot compensate for an unhealthy diet or sedentary lifestyle. (Source: Freepik)

Listen to this article
Your browser does not support the audio element.

Contrary to what is seen on social media about the latest trend of ginger oil reducing belly fat, please understand that weight loss requires a holistic approach. To achieve weight loss or reduce belly fat, it is important to follow a protocol of balanced diet, regular exercise and lifestyle modifications. Relying solely on ginger oil or a single ingredient is unlikely to produce significant results. A sustainable weight loss journey involves creating a calorie deficit, increasing physical activity, and adopting healthy habits for long-term success.

Incorporating ginger into a balanced diet can be beneficial for overall health and well-being. It can add flavor to meals, aid in digestion, and provide antioxidant and anti-inflammatory effects. However, it should be noted that ginger alone cannot compensate for an unhealthy diet or sedentary lifestyle. It is important to focus on general dietary patterns and lifestyle habits for weight management.

Myth: Ginger oil directly affects belly fat and promotes weight loss.

Done:There is no scientific evidence to support the claim that ginger oil alone directly affects belly fat or causes significant weight loss. While ginger has been studied for its potential health benefits, such as anti-inflammatory and antioxidant properties, its effects on weight loss aren’t well established.

Myth: Applying ginger oil topically to the belly area reduces fat.
Done:The idea that applying ginger oil topically to the belly area can reduce fat is a myth. Fat loss occurs through a combination of factors, including a balanced diet, regular moderate-intensity physical activity, and overall calorie expenditure. Topical application of ginger oil has no direct impact on fat metabolism.

Myth: Ginger may indirectly aid weight management.
Done:While ginger oil itself may not directly promote belly fat loss, consuming ginger in various forms, such as fresh ginger root or ginger tea, may have potential weight management benefits. Ginger is known to have thermogenic properties, meaning it can slightly raise your body temperature and potentially boost your metabolism. However, the effects are minimal, so ginger alone isn’t a magic weight-loss fix.

Myth: Ginger can aid digestion and reduce bloating
Done:Ginger has traditionally been used to ease digestive discomfort and reduce bloating. It can help stimulate the production of digestive enzymes and improve overall digestion. By reducing bloating and improving digestive function, ginger may contribute to a flatter tummy appearance, but it won’t specifically target fat in that area.

Myth: Ginger oil gets rid of cellulite
Done:There is no scientific evidence to support the claim that ginger oil gets rid of cellulite. Cellulite is a common condition that occurs when fat deposits push through the connective tissue under the skin, resulting in a dimpled appearance. While ginger oil can have moisturizing and toning effects on the skin, it cannot directly eliminate cellulite.

Ginger may indirectly support weight management by aiding digestion and reducing bloating, but its effects aren’t dramatic or specific to belly fat. Always remember that fat loss does not happen overnight. It requires sustained discipline of a holistic health regimen. The bigger issue is making sure the weight isn’t regained, and that requires a long-term commitment to a holistic regimen that you can easily stick to and not trash as a temporary fix.

First published on: 2023-06-07 at 17:22 CEST



#Ginger #Oil #Melt #Belly #Fat #Trendy #solutions #dont #work

Ozempic: Study finds it could work in pill form

A woman is seen looking at her phone.

A woman is seen looking at her phone.Share on Pinterest
The drug Ozempic may become available in pill form. FreshSplash/Getty images
  • Novo Nordisk is testing whether an Ozempic pill is as effective as the popular injectable form of the drug.
  • Early research has shown promising results.
  • Semaglutide is a drug developed to treat type 2 diabetes by regulating insulin by mimicking a hormone in the body called GLP-1.

The weight loss journey for many people is a struggle, but with the recent surge and use of drugs like Ozempic and Wegovy, people are finding it easier to lose the extra weight.

Semaglutide, the drug in Ozempic and Wegovy, is currently administered into the body through injections. However, pharmaceutical companies are experimenting with an oral pill form of this weight loss drug with promising results.

In a recent press release, Novo Nordisk, the company that makes Ozempic and Wegovy, announced promising results in a Phase 3a study evaluating the efficacy and safety of this weight-management drug.

The study involved 667 adults with obesity or overweight with at least one comorbidity. It found that the 50 mg oral form of semaglutide resulted in a 15.1% weight loss compared to 2.4% in the placebo group.

Martin Holst Lange, executive vice president of development at Novo Nordisk, said he was pleased with the results, and the choice between a daily tablet or a weekly injection for obesity has the potential to give patients and healthcare professionals the opportunity to choose what best suits the individual’s treatment preferences, in a corporate statement.

Dr. Louis J. Aronne, director of the Comprehensive Weight Management Center at Weill Cornell Medicine, finds the oral option compelling and creates a greater outreach.

Many people prefer oral dosing. Once-a-week injections, however, are very simple to administer and in some ways more cost-effective. Oral dosing increases the range of people who can be treated with these drugs, he tells Healthline.

According to Harvard University, approximately 69% of US adults are considered overweight or obese. THE Center for Disease Control and Prevention reports that as of 2020, the prevalence of severe obesity has increased from 4.7% to 9.2%.

Obesity and being overweight increase your risk of heart disease, stroke and diabetes and can increase your risk of developing some types of cancer.

Semaglutide is a drug developed to treat type 2 diabetes by regulating insulin by mimicking a hormone in the body called GLP-1.

GLP-1 can also tell the brain that the stomach is full, even if it isn’t, resulting in decreased appetite, less desire to eat, and eventual weight loss.

Ozempic is currently approved for the treatment of type 2 diabetes, but Wegovy, which uses the same drug semaglutide, has been approved for weight loss.

In their current form, these drugs are currently being administered by injection into the waist, thigh, or even the upper arm once a week. Sometimes this can not only be uncomfortable for patients, but also create more hesitation in taking medications.

An oral form of semaglutide is already available under a different brand name, Rysbelsus. However, at the prescribed dose, it has not shown efficacy in regards to weight loss. This drug is prescribed at 14mg at most and at that dose it does not help in weight loss.

Novo Nordisk’s recent oral drug study showed weight loss results at 50mg.

It may be likely that higher doses taken by mouth than injected subcutaneously could result in more gastrointestinal distress for some patients, but that remains to be seen once the drug makes its way to market, said Dr. Sahar Takkouche, chief expert in Bariatric and Obesity Medicine and Assistant Professor in the Division of Diabetes, Endocrinology and Metabolism at Vanderbilt University Medical Center in Tennessee.

Some patients may be more tolerant than others when it comes to side effects as there is variation with any drug.

Despite the newfound popularity of these drugs, they come with side effects, both in injectable and oral forms. The study showed that the most common side effect associated with these drugs is gastrointestinal upset. However, gastrointestinal problems are also associated with injection forms including nausea, constipation, diarrhea, vomiting, belching, and generalized abdominal pain.

With semaglutide causing gastrointestinal distress, Aronne recommends taking them on an empty stomach at least half an hour away from food and other medications, and you can’t take them with all other medications.

Besides the side effects, these drugs can also be expensive. Some insurance companies cover these drugs for diabetes treatment, but many don’t cover them for weight loss that costs people about $1,000 out of pocket a month for treatment.

Many insurance companies do not recognize obesity as a medical condition and view the treatment of this disease as purely cosmetic, says Takkouche.

He continues, this paradigm is invalid and puts our patients and the US population at risk of further decline while increasing the cost of health care for all.

Other companies are quickly racing to create oral drugs for diabetes and weight loss as well.

Pfizer is currently developing danuglipron, another oral drug for diabetes and weight loss. The company recently published a study in the journal JAMA network open as for a tablet twice a day which is said to be taken with food, which is different from oral forms of semaglutide.

Similarly, for semaglutide, this drug mimics GLP-1 to not only help regulate insulin, but also tell the brain that the stomach is full and help regulate weight loss.

While these drugs are compelling, not all of them are the perfect fit for them.

The best candidates for this drug are patients with a BMI greater than 30 or a BMI greater than 27 plus an obesity-related comorbidity such as type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea or fatty liver, Takkouche explained.

Drug therapy is a compelling way for many to lose weight if diet and exercise are not suitable options for an individual and with different companies working to approve oral medications, the number of people eligible for these drugs could increase.

Dr. Rajiv Bahl, MBA, MS, is an emergency medicine physician, board member of the Florida College of Emergency Physicians, and health writer. You can find it at RajivBahlMD.

#Ozempic #Study #finds #work #pill #form

More work needed to meet LDL goals: SANTORINI

More work needed to meet LDL goals: SANTORINI

MANNHEIM More patients with high cardiovascular risk are reaching their LDL-cholesterol goals probably thanks to combination lipid-lowering therapy, but much work remains to be done, suggest data from a European registry.

More than 7200 patients with baseline and 1-year cholesterol measurements from the SANTORINI registry were included in the current analysis.

The results showed that the percentage of patients who met their LDL cholesterol target increased from 21% to 31%, with an average decrease in mean levels of 0.4 mmol/L in both the high and very high risk groups. .

The research was presented at the 91st Congress of the European Atherosclerosis Society (EAS) on May 23.

This decrease in LDL cholesterol levels “is largely driven, thankfully, by those people who are not on lipid-lowering medication who are on something, and also by many other patients switching to combination therapies,” such as a statin plus ezetimibe, said study presenter Kausik Ray, MD, PhD, professor of public health at Imperial College London, London, UK, and chair of EAS.

“However, at the population level, we are not bringing our population to the target because we are not putting enough patients on combination therapy. The mantra must be to move to combination therapy rather than monotherapy,” and this it starts with your own risk assessment,” Ray said.

He also admitted that the SANTORINI registry represents the “best case scenario” because it includes people willing to participate in the research.

Ray noted that when you look at electronic health record data, the picture is “worse than this.”

“Sad Work”

Asked for comment, session co-chair Andreas Zirlik, MD, PhD, described the results as “very disappointing.”

“We now have so many good tools to curb LDL cholesterol, and we’re still doing a terrible job,” Zirlik, Head of the Department of Cardiology and President of the University Heart Center Graz, LKH-University Hospital and Medical University of Graz, Graz, Austria, said heart.org | Medscape Cardiology.

Referring to the overall increase of 10% of patients in the registry who met the goal, he said: “It’s a little bit better, but is it really worth celebrating? No.”

Zirlik suggested that, with most studies showing only a “small fraction” of patients receiving combination therapy, “we need a recommendation, as we have now in blood pressure therapy, to start proactively with a combination “.

He also believes that while “the lower the better” and “the sooner the better” are “great slogans” for lipid management, “maybe we need a little more granularity in the higher-risk group because it’s like if anyone had a vascular phenotype it is higher risk.

“But there are definitely patients out there, for example those who have really had an event, who should have very strict and speedy recommendations for more aggressive therapy,” beyond just a combination, Zirlik said.

behavior over time

Ray began his presentation by noting that, normally, registries provide a snapshot of current care practices, but with the 1-year follow-up from the SANTORINI registry, they were able to observe physician behavior over time and ask some questions. key questions.

Note these include: What care do healthcare providers provide at each of the participating sites? What changed in that follow-up year? What did that change entail?

Ray also pointed out that SANTORINI is the first registry conducted in Europe by the updated 2019 ESC/EAS guidelines for the management of dyslipidemias. The guidelines “moved the goalposts” for three of the LDL cholesterol risk categories, with two of those hard to reach, he said.

In particular, the objectives have become:

  • High-risk: < 1.8 mmol/L (< 70 mg/dL)

  • Very high risk: < 1.4 mmol/L (< 55 mg/dL)

  • For both: 50% reduction in LDL cholesterol

“What we have forgotten to tell people is that the goalposts have shifted due to the use of combination therapy,” he said.

SANTORINI enrolled 9136 patients with high and very high cardiovascular risk between March 2020 and February 2021 in 623 centers in 14 European countries and followed them up to 31 May 2022.

For the current analysis, lipid management was assessed in 7120 patients who had available LDL cholesterol levels at both baseline and 1-year follow-up.

They had a mean age of 65 and 72.1% were men. “Not surprisingly, there are a lot of people with established cardiovascular disease, smoking, high blood pressure,” Ray noted, and the mean LDL cholesterol level was 2.42 mmol/L (93.53 mg/dL).

Overall, the mean LDL-cholesterol level dropped to 1.98 mmol/L, with the percentage of patients meeting the goal increasing from 21.5% to 32.1%, with similar results seen in both high- and very high-risk groups.

“Each group is moving about 0.4 mmol/L,” Ray said, “which translates into about 10 percent more people hitting the target.”

“So, the question now is: where did it come from? Who are the ones that are moving?”

It showed that, over the course of the study, the percentage of patients receiving no lipid-lowering therapy decreased from 21.6% to 3.0%.

There was a small increase in monotherapy use, from 50.9% to 55.4% of patients, which was largely due to the increase in statin use.

There was, however, a much larger increase in the proportion of patients receiving the combination therapy, from 27.5% to 41.7%. This was largely due to the increase in the use of a statin plus ezetimibe, with smaller increases for the proprotein convertase inhibitor subtilisin/kexin type 9 (PCSK9) combinations.

Again, similar patterns were seen in both the high- and very high-risk groups, albeit with a greater switch to combination therapies in the high-risk group, from 29.9% to 45.3%.

Turning to goal achievement, Ray showed that 28.2% of high-risk patients who achieved their baseline LDL cholesterol target were receiving monotherapy, with statin therapy being the most common, while 36, 6% had combination therapy.

The most used combination was PCSK9 inhibition plus another drug, in 52.1% of patients, while 32.7% took a statin plus ezetimibe. This pattern was mirrored in the high risk group.

The study was sponsored by Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo company. Ray discloses relationships with Amgen, Sanofi, Regeneron, Daiichi Sankyo, Pfizer, Viatris, Abbott, AstraZeneca, Lilly, Kowa, Novo Nordisk, Boehringer Ingelheim, Esperion, Cargene, Resverlogix, SCRIBE, Novartis, Silence Therapeutics, CRISPR, Bayer, New Amsterdam Pharmaceuticals, BI, Vaxxinity, PEMI-31.

91st Congress of the European Atherosclerosis Society 2023. Presented on 23 May 2023. Abstract 1536

For more news, follow Medscape on Facebook, ChirpingInstagram and YouTube


#work #needed #meet #LDL #goals #SANTORINI

DNA research is helping investigators track down suspects in unsolved cases. But how does it work? – The Boston globe

DNA research is helping investigators track down suspects in unsolved cases.  But how does it work?  - The Boston globe

First, IGG is a methodology, David Gurney, an assistant professor at Ramapo College in New Jersey who directs the school’s Investigative Genetic Genealogy Center, said in an email, using the technique’s acronym.

IGG practitioners combine genetic genealogy with desk research to produce clues in violent crime cases and to help identify human remains, according to Gurney.

These clues are then confirmed by law enforcement using traditional DNA methods, he continued.

Historically, investigators had to rely on a federal DNA database containing profiles of people previously arrested. If a suspicious DNA profile was not in the system, called CODIS, that person could not be identified.

But ancestry sites have changed the game.

Now the authorities can present an attackers autosomal DNA profiling to two commercial genealogical databases, GEDmatch and FamilyTree DNA, which are used by consumers to trace their ancestry or locate relatives. Customers must consent before their information is shared with law enforcement agencies.

The GEDMatch website states that customers, when uploading their DNA, can choose the level of privacy they want for their DNA kit.

Customers who select the Public Opt-In option, the site says, have their DNA entered into a database that is open to users (including law enforcement agencies) attempting to identify unidentified human remains and to law enforcement agencies who attempt to identify perpetrators of violent crimes. … The operators of GEDmatch encourage everyone to check this option.

The companies eventually provide law enforcement with a list of relatives and the percentage of DNA they share with the submitted sample.

In many cases, a person’s closest genetic relative may be a third or more distant cousin, Cairenn Binder, who heads Rampao College’s IGG certification program, said in an email.

The more distant the genetic relatives, the more difficult the case will be, Binder said.

While not all customers on the sites agree to make their DNA profile available to investigators, many do.

Binder pointed to a 2022 study that found more than 500,000 users of GEDMatch had decided to make their profiles available to law enforcement agencies. But not all genetic testing companies make customer DNA profiles available for law enforcement comparisons.

The only companies that allow law enforcement searches are FamilyTreeDNA and GEDmatch Pro, Binder said. AncestryDNA has been unsuccessfully sued many times.

Gurney said Ancestry and MyHeritage have by far the largest number of DNA profiles in their possession.

[I]If they changed their terms of service to allow for IGG research, it would dramatically impact the number of cases that would be resolved with IGG’s help, Gurney said.

Requests for comment were sent to Ancestry and MyHeritage on Tuesday.

In the case of New Jersey attorney Matthew James Nilo, 35, detectives used technology to identify him as a suspect in April and then staked out him in the New York area. according to prosecutors and court records.

Ultimately, investigators collected DNA from glasses and utensils they saw Nilo use at a company event, prosecutors said. When they analyzed the DNA, it presumably matched the samples in the rape kits from the 2007 and 2008 assaults. Nilo pleaded not guilty.

Gurney said the courts have consistently upheld this practice [of surreptitious DNA collection in public events] and found that it doesn’t violate the 4th amendment since individuals don’t have a privacy interest in the DNA they discarded in public.

Law enforcement officials did not say which relative of Nilos submitted a DNA profile to an ancestor site that ultimately led to him being identified as the alleged perpetrator.

Most of the people who have uploaded their DNA profiles to GEDmatch and FamilyTreeDNA are of Western European descent, Gurney said. The IGG can and does provide guidance in cases involving people of other ethnicities, but on average those cases will take longer, she said.

In addition to identifying suspects, genetic genealogy has also been used to determine the identity of murder victims. Last year, the FBI announced it had identified The Lady of the Dunes, a Cape Cod mystery that had eluded law enforcement for nearly 50 years.

Some civil rights advocates have raised privacy concerns about investigative genetic genealogy and have called for increased regulation of company databases and oversight of the police, labs and genealogists involved in the process. And advocates for sexual assault survivors say these types of cold-case strategies need to be executed in a way that continues to give victims a voice in the process.

A major technology breakthrough, experts say, is putting suspects with clean records on law enforcement’s radar, since people who haven’t been arrested aren’t in the federal CODIS system of DNA samples.

This happens over and over again, said Barbara Rae-Venter, an investigative genetics genealogy consultant who works with police across the country to help identify murder and rape suspects, in a recent interview. The people we identify have no priors. I’m not on anyone’s radar.

But with investigative genetic genealogy, Rae-Venter said, authorities can identify people you otherwise wouldn’t be able to identify.

Although it may take some time.

The process can take from a few hours to many years, Binder said. To give some examples, I worked in the team that he identified [serial killer John Wayne] Gacy Victim 5 in eight hours, but I worked the Apache Junction Jane Doe case [in Arizona] for nearly five years and remains unidentified.

Material from previous Globe stories was used in this report.


Travis Andersen can be reached at [email protected].

#DNA #research #helping #investigators #track #suspects #unsolved #cases #work #Boston #globe

Why does diabetes drug Mounjaro work so well for weight loss

Mounjaro diet drug

Mounjaro diet drug

Mounjaro diet drug

Credit – Getty Images Sandy Huffaker for The Washington Post

The latest diabetes drug semaglutide, better known by the brand names Ozempic, Wegovy and Rybelsus, is attracting attention for its ability to both control blood sugar and cause weight loss. But doctors and patients alike predict that the most powerful of these drugs is yet to come, as the U.S. Food and Drug Administration is considering approving Eli Lilly’s drug tyrzepatide (trade name: Mounjaro) for the loss of weight by the end of the year.

In studies that Lilly has submitted to the FDA, the company has shown that Mounjaro, which is already approved to treat type 2 diabetes, can reduce body mass among users at its highest dose by up to 15%. While semaglutide targets one molecule, glucagon-like peptide-1 (GLP-1), involved in insulin secretion, tirzepatide is the first to target two: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). ).

In a new study published in Metabolism of nature, an international group of researchers, in collaboration with scientists from Eli Lilly and Novo Nordisk (the creator of Ozempic and Wegovy), sought to understand how tyrzepatide produces its strong effects on blood sugar and weight. Working with both mice and cultures of human insulin-producing pancreatic cells, the team conducted a series of experiments to better understand the factors behind the drugs’ dual action.

More from TIME

The historical narrative in the field has been that GIP is doing everything GLP-1 is doing, just not as well, says Jonathan Campbell, an associate professor of medicine at Duke University and the study’s senior author. Researchers have known that GLP-1 acts on cells in the pancreas and stimulates the production of insulin, which breaks down glucose in the body. It also works on the digestive system, suppressing hunger signals sent to the brain and curbing appetite. GIP has similar effects, but they are generally not as powerful.

The scientists therefore expected to find that tyrzepatide worked primarily by activating GLP-1 receptors in the body and wondered whether GIP would have an additional impact. Since the molecules are very similar, targeting both would not necessarily lead to an additive effect. Instead, the two entities could be competing to bind to the same cell receptors, both trying to go through the same door at the same time, Campbell says.

But to their surprise, the team found that tirzepatide actually triggers a potent GIP response. GIP was imperative, Campbell says. Indeed, in experiments on insulin-producing pancreatic cells donated by eight volunteers, the researchers found that if GIP was blocked in these cells, preventing the drug from binding to GIP receptors, the drug had no effect on stimulating insulin production. . When the GIP receptors weren’t blocked, the cells produced insulin.

This was surprising to us, and the opposite of what we thought, she says.

to know more: What’s missing from Ozempic’s obsession with food and health

The reason may have something to do with the differences between mice and humans. Scientists rely heavily on mouse models to understand how things like GIP and GLP-1 work in living organisms, but it turns out that GIP receptors are different in human cells. While the genetic sequences for GLP-1 receptors in mice and humans are identical, the sequences for GIP receptors in the two species are not. This is a problem, since the most efficient way to understand how GIP works is to study human versions of the receptors in mice. All of the data examining tyrzepatide mechanistically has been obtained primarily in mouse models, says Campbell. So we thought it was important for researchers to know that there are confounding variables.

The studies are an intriguing first step in answering questions about whether the latest class of GLP-1-based diabetes and weight-loss drugs might be more effective when combined with GIP-based drugs. More studies would be needed to explore whether targeting not just one, but several processes involved in insulin production and weight might be more effective. If that were the case, doctors would have different tools that would give them more options for treating people, Campbell says.

This study shows that for insulin secretion, which is an important biological action for glucose control, GIP appears to be very, very important, he says. Taking that scientific tip, Campbell hopes to build on these findings by studying GLP-1 and GIP in larger numbers of human cell samples. And since the volunteers in the current trial spanned a range of BMIs but didn’t have diabetes, he says it’s important to also include cells from people with the condition to better isolate the most efficient way to control blood sugar and weight.

#diabetes #drug #Mounjaro #work #weight #loss